# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

# Submitter name, address, contact

Roche Diagnostics 9115 Hague Road Indianapolis, IN 46250

Contact person: Stephanie Greeman   
• Phonc: (317) 521-2458   
• FAX: (317) 521-2324   
• email: stephanie.greeman@roche.com   
Secondary contact :   
Kay Taylor   
• Phone: (317) 521-3544   
• FAX: (317) 521-2324   
• email: kay.taylor@roche.com

Date Prepared: May 9, 2008

# Device Name

Proprietary name: (1) Elecsys Anti-CCP Immunoassay (2) Elecsys PreciControl CCP

Common name: (1) Anti-CCP Assay ) PreciControl Anti-CCP

Classification name: (1) Antibodies, Anti-Cyclic Citrullinated Peptide (2) Single (specified) analyte controls (Assayed and Unassayed)

Continued on next page

Device Description

(1) The Elecsys Anti-CCP immunoassay is a two step IgG-capture test principle immunoassay with streptavidin-coated microparticles and electrochemiluminescence detection. Results are determined using a calibration curve that is generated specifically on each instrument by a 2 point calibration and a master curve provided with the reagent bar code.

The Elecsys Anti-CCP reagent kit consists of a Reagent Pack (R1, R2 and M[streptavidin-coated microparticles]) and lyophilized calibrators 1 and 2.

(2) The Elecsys PreciControl Anti-CCP is a lyophilized product consisting of human serum with added Anti-CCP antibody (human) in two concentration ranges. During manufacture, the antibody is spiked into the matrix at the desired concentration levels.

Note: The reagent is packaged with calibrators; controls are packaged separately.

Intended use / Indications for Use

(1) Elecsys Anti-CCP immunoassay: Immunoassay for the in vitro semiquantitative determination of human IgG autoantibodies to cyclic citrullinated peptides in human serum and plasma. The results of the assay are intended to be used as an aid in the diagnosis of rheumatoid arthritis in combination with other clinical and laboratorv findings.

The electrochemiluminescence immunoassay "ECLIA" is intcndcd for use on Elecsys and cobas e immunoassay analyzers.

(2) Elecsys PreciControl Anti-CCP is used for quality control of the Elccsys Anti-CCP immunoassay on the Elecsys and cobas c immunoassay analyzers.

# Substantial equivalence

The Elecsys Anti-CCP Test System is substantially cquivalent to other devices legally marketed in the United States.

(1) Elecsys Anti-CCP Immunoassay is equivalent to the Eurodiagnostica IMMUNOSCAN RA Anti-CCP Test Kit (K052133). Both products arc intended for use in the semi-quantitative determination of human IgG antibodies to cyclic citrullinated peptides in human serum.

(2) Elecsys PreciControl Anti-CCP is equivalent to the controls contained in the Eurodiagnostica IMMUNOSCAN RA Anti-CCP Test Kit (K052133).

Substantial equivalencecomparison

The following table compares the Elecsys Anti-CCP Immunoassay with the predicate device.

<table><tr><td rowspan=1 colspan=3>Immunoassay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Elecsys Anti-CCP Assay</td><td rowspan=1 colspan=1>Predicate DeviceEurodiagnostica IMMUNOSCANRA Anti-CCP Test Kit (K052133)</td></tr><tr><td rowspan=1 colspan=1>Intended Use /Indication forUse</td><td rowspan=1 colspan=1>Immunoassay for the in vitro semi-quantitative determination of humanIgG autoantibodies to cycliccitrullinated peptides in humanserum and plasma. The results ofthe assay are intended to be used asan aid in the diagnosis ofrheumatoid arthritis in combinationwith other clinical and laboratoryfindings.The clectrochemiluminescenceimmunoassay &quot;ECLIA&quot; is intendedfor use on Elecsys and cobas eimmunoassay analyzers.</td><td rowspan=1 colspan=1>The Immunoscan RA anti-CCP test kitis an enzyme-linked immunosorbentassay (ELISA) for detection and semi-quantitation of IgG antibodies toCyclic Citrullinated Peptides (CCP) inhuman sera. The assay is used todetect antibodies in a single serumspecimen. The results of the assay areto be used as an aid to the diagnosis ofRheumatoid Arthritis (RA), inconjunction with other laboratory andclinical findings. The analysis shouldbe performed by trained laboratoryprofessionals.</td></tr><tr><td rowspan=1 colspan=1>Assay Protocol</td><td rowspan=1 colspan=1>IgG-capture test principle</td><td rowspan=1 colspan=1>ELISA - IgG adsorption</td></tr><tr><td rowspan=1 colspan=1>DetectionProtocol</td><td rowspan=1 colspan=1>electrochemiluminescenceimmunoassay (ECLIA)</td><td rowspan=1 colspan=1>photometric</td></tr><tr><td rowspan=1 colspan=1>Traceability/Standardization</td><td rowspan=1 colspan=1>Standardized against acommercially available anti-CCPassay</td><td rowspan=1 colspan=1>Not given</td></tr><tr><td rowspan=1 colspan=1>CalibrationInterval</td><td rowspan=1 colspan=1>After 1 month (28 days) whenusing the same reagent lotAfter 7 days (when using thesame reagent kit on the analyzer)As required: e.g. quality controlfindings outside the specifiedlimits</td><td rowspan=1 colspan=1>Calibrate with each test</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Human serum and plasma</td><td rowspan=1 colspan=1>Human serum</td></tr></table>

The following table compares the Elecsys Anti-CCP Immunoassay with the predicate device.

Substantial equivalence - comparison   

<table><tr><td rowspan=1 colspan=3>Immunoassay Comparison, continued</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Elecsys Anti-CCP Assay</td><td rowspan=1 colspan=1>Predicate DeviceEurodiagnostica IMMuNOSCANRA Anti-CCP Test Kit (K052133)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Reagent Stability  Unopened up to the statedexpiration date stored at 2  8°COn all analyzers:1 week ormaximum of 40 hours on theanalyzer; up to 4 weekswhen stored alternately inthe refrigerator and on theanalyzer.</td><td rowspan=1 colspan=1>Store kit at 2  8°C in a dark place upto stated expiration date.</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>Anti-CCP calibrators 1 and 2supplied with kit</td><td rowspan=1 colspan=1>Five levels of calibrators supplied withkit</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Elecsys PreciControl Anti-CCP 1and 2</td><td rowspan=1 colspan=1>Reference, positive, and negativecontrols supplied with kit</td></tr><tr><td rowspan=1 colspan=1>Expected Values</td><td rowspan=1 colspan=1>Positive: ≥ 17 U/mL</td><td rowspan=1 colspan=1>Negative: &lt; 25 U/mLPositive: ≥ 25 U/mL</td></tr><tr><td rowspan=1 colspan=1>Instrument</td><td rowspan=1 colspan=1>Elecsys 2010, MODULARANALYTICS E170, cobas e 411,cobas e 601</td><td rowspan=1 colspan=1>spectrophotometer</td></tr><tr><td rowspan=1 colspan=1>MeasuringRange</td><td rowspan=1 colspan=1>8 - 1000 U/mL (defined by the limitof detection and the maximum ofthe master curve)</td><td rowspan=1 colspan=1>1.6- 1600 U/mL</td></tr></table>

Substantial equivalence - comparison

The following table compares the performance of Elecsys Anti-CCP Immunoassay with the predicate device.

<table><tr><td colspan="3">Immunoassay Performance Comparison</td></tr><tr><td>Feature</td><td>Elecsys Anti-CCP Assay</td><td>Predicate Device Eurodiagnostica IMMuNOSCAN RA Anti-CCP Test Kit (K052133)</td></tr><tr><td>Precision</td><td>Elecsys 2010 and cobas e 411: Total 3.1% CV @ 16.9 U/mL 4.5% CV @ 356 U/mL 3.0% CV @ 24.6 U/mL 2.5% CV @ 137 U/mL Within-run</td><td>Intra-assay Precision: 12.8%CV @ 1007.4 U/mL 6.5% CV @ 240.1 U/mL 7.0%CV @ 95.7 U/mL 8.4% CV @ 51.7 U/mL 8.1% CV @ 33.6 U/mL 4.3% CV @ 88.1 U/mL</td></tr><tr><td></td><td>0.6% CV @ 16.9 U/mL 2.3% CV @ 356 U/mL 1.0% CV @ 24.6 U/mL 1.4% CV @ 137 U/mL</td><td>Inter-assay Precision: 11.7% CV @ 1105.9 U/mL 7.9% CV @ 257.4 U/mL 6.0% CV @ 93.1 U/mL 7.8% CV @ 52.5 U/mL 14.5% CV @ 33.3 U/mL 17.7% CV @ 94.9 U/mL</td></tr></table>

The following table compares the performance of Elecsys Anti-CCP Immunoassay with the predicate device.

Substantial equivalence - comparison   

<table><tr><td colspan="3">Immunoassay Performance Comparison, continued</td></tr><tr><td>Feature</td><td>Elecsys Anti-CCP Assay</td><td>Predicate Device Eurodiagnostica IMMUNOSCAN RA Anti-CCP Test Kit (K052133)</td></tr><tr><td>LoQ (Functional Sensitivity)</td><td>8 U/mL</td><td>N/A</td></tr><tr><td>Limit of Blank (LoB)</td><td>≤ 7 U/mL</td><td>N/A</td></tr><tr><td>Limit of Detection LoD (Analytical Sensitivity</td><td>≤ 8 U/mL</td><td>N/A</td></tr><tr><td>LDL (Lower Detection Limit)</td><td>N/A</td><td>1.6 U/mL</td></tr><tr><td>Limitations</td><td>The assay is unaffected by: Bilirubin: &lt; 25 mg/dL Hemoglobin: &lt; 0.5 g/dL Intralipid: &lt; 1500 mg/dL Biotin: &lt; 30 ng/mL In patients receiving therapy with high biotin doses (i.e. &gt;5 mg/day), no sample should be taken until at least 8 hours after the last biotin administration. Interference was observed from Rheumatoid factor above concentrations of 150 IU/mL.</td><td>The assay is unaffected by: Bilirubin: ≤ 0.2 mg/mL • Hemoglobin: ≤ 400 mg/dL Lipid: ≤ 15 mg/mL Rheumatoid factor: ≤ 200 IU/mL</td></tr></table>

The following table compares the performance of Elecsys Anti-CCP Immunoassay with the predicate device.

Substantial equivalence - comparison   

<table><tr><td colspan="3">Immunoassay Performance Comparison, continued</td></tr><tr><td>Feature</td><td>Elecsys Anti-CCP Assay</td><td>Predicate Device Eurodiagnostica IMMUNOSCAN RA Anti-CCP Test Kit (K052133)</td></tr><tr><td>Limitations, continued</td><td>Interference with pathologic • levels of unspecific IgG can not be excluded. However, the coincidence of RA and gammopathy in one patient has been reported to be very low. The anti-CCP test results can be false negative in patients with hypergammaglobulinaemia. Results from patients suffering from this disorder should not be used for diagnostic purposes. In vitro tests were performed on 18 commonly used pharmaceuticals and in addition on methrotrexate and prednisolone. No interference with the assay was found. As with all tests containing monoclonal mouse antibodies, erroneous findings may be obtained from samples taken from patients who have been treated with monoclonal mouse antibodies or have received them for diagnostic purposes.</td><td></td></tr></table>

Substantial equivalence - comparison

The following table compares the performance of Elecsys Anti-CCP Immunoassay with the predicate device.

<table><tr><td rowspan=1 colspan=2>Immunoassay Performance Comparison, continued</td><td rowspan=1 colspan=1>arison, continued</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Elecsys Anti-CCP Assay</td><td rowspan=1 colspan=1>Predicate DeviceEurodiagnostica IMMuNOSCANRA Anti-CCP Test Kit (K052133)</td></tr><tr><td rowspan=1 colspan=1>Limitations,continued</td><td rowspan=1 colspan=1>The risk of interference frompotential immunologicalinteractions between testcomponents and rare sera hasbeen minimized by the inclusionof suitable additives.In rare cases, interference due toextremely high titers ofantibodies to streptavidin andruthenium can occur. The testcontains additives whichminimize these effects.For diagnostic purposes, theresults should always beassessed in conjunction with thepatient&#x27;s medical history,clinical examination and otherfindings.</td><td rowspan=1 colspan=1>b</td></tr></table>

Substantial equivalence - comparison

The following table compares the performance of Elecsys Anti-CCP Immunoassay with the predicate device.

<table><tr><td rowspan=1 colspan=6>Immunoassay Performance Comparison, continued</td><td rowspan=1 colspan=5></td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=5>Elecsys Anti-CCP Assay</td><td rowspan=1 colspan=5>Predicate DeviceEurodiagnostica IMMUNOSCANRA Anti-CCP Test Kit (K052133)</td></tr><tr><td rowspan=11 colspan=1>MethodComparison</td><td rowspan=2 colspan=5>Elecsys Anti-CCP was comparedanti-CCP microtiter plate ELISAassay (IMMUNOSCAN RA Anti-CCP test kit).1606 samples tested using a cut-offof ≥ 17 U/mL for the Elecsys Anti-CCP assay.</td><td rowspan=1 colspan=5>Percent agreement of the ImmunoscanRA CCP kit compared to an alternativeCCP ELISA:A total of 320 frozen retrospective serawere assayed. 175 samples were fromRA patients and 145 samples werenormals from a blood bank. Thefollowing table summarizes the results.</td></tr><tr><td rowspan=1 colspan=5>Alternative ELISA</td></tr><tr><td></td><td></td><td></td><td></td><td rowspan=5 colspan=2>Immuno-scanRATotalCCP446Kit</td><td rowspan=3 colspan=1>Positive</td><td rowspan=2 colspan=1>Positive</td><td rowspan=2 colspan=1>Negative</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>N=1606</td><td rowspan=2 colspan=1></td><td rowspan=2 colspan=2>ImmunoscanAnti-CCP</td></tr><tr><td rowspan=1 colspan=1>135</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>141</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>178</td><td rowspan=1 colspan=1>179</td></tr><tr><td rowspan=4 colspan=1>ElecsysAnti-CCP</td><td rowspan=1 colspan=1>$\frac }$</td><td rowspan=1 colspan=1>428</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>446</td><td rowspan=2 colspan=1>Total</td><td rowspan=2 colspan=1>136</td><td rowspan=2 colspan=1>184</td><td rowspan=2 colspan=1>320</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>1134</td><td rowspan=1 colspan=1>1160</td><td></td></tr><tr><td rowspan=2 colspan=1>total</td><td rowspan=2 colspan=1>454</td><td rowspan=2 colspan=1>1152</td><td rowspan=2 colspan=1>1606</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=2 colspan=5>Positive Percent Agreement = 99.3%(95% CI = 93.2 = 100%)Negative Percent Agreement = 96.7%(95% CI = 81.6 - 99.9%)Overall Percent Agreement = 97.8%(95% CI = 93.2 - 100%)The 95% confidence interval (CI) wascalculated using the exact method.</td></tr><tr><td rowspan=1 colspan=5>Positive Percent Agreement = 94.3%(95% CI = 91.7 − 96.2)Negative Percent Agreement = 98.4%(95% CI = 97.5 - 99.1)Total Pcrcent Agreement = 97.3%(95% CI = 96.3 - 98.0)</td></tr><tr><td rowspan=1 colspan=1>Hook Effect</td><td rowspan=1 colspan=5>No high-dose hook effect at anti-CCP concentrations up to 7000U/mL</td><td rowspan=1 colspan=5>Not given.</td></tr></table>

The following table compares the calibrators supplied with the Elecsys AntiCCP immunoassay kit with the calibrators supplied with the predicate device.

Substantial equivalence - comparison   

<table><tr><td rowspan=1 colspan=3>Calibrator Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Elecsys Anti-CCP Assay</td><td rowspan=1 colspan=1>Predicate DeviceEurodiagnostica IMMuNOSCANRA Anti-CCP Test Kit (K052133)</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>5</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Lyophilized</td><td rowspan=1 colspan=1>Liquid</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>human serum</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>AnalyteConcentration(Anti-CCPantibodics;human)</td><td rowspan=1 colspan=1>Calibrator 1: 20 U/mLCalibrator 2: 200 U/mL</td><td rowspan=1 colspan=1>Calibrator A: 1600 U/mLCalibrator B: 800 U/mLCalibrator C: 200 U/mLCalibrator D: 50 U/mLCalibrator E: 25 U/mL</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Unopened:Until expiration date.Reconstituted:On the analyzers at 20  25°C:up to 2 hoursAt -20°C: up to 4 weeks (freezconly once).After thawing: use only once.</td><td rowspan=1 colspan=1>N/A</td></tr></table>

Substantial equivalence - comparison

The following table compares the calibrators supplied with the Elecsys AntiCCP immunoassay kit with the calibrators supplied with the predicate device.

<table><tr><td colspan="3">Calibrator Comparison, continued</td></tr><tr><td>Feature</td><td>Elecsys Anti-CCP Assay</td><td>Predicate Device Eurodiagnostica IMMUNOSCAN RA Anti-CCP Test Kit (K052133)</td></tr><tr><td>Handling</td><td>Dissolve carefully the contents of one bottle by adding exactly 1.0 mL of distilled water and allow to stand closed for 15 minutes to reconstitute. Mix carefully, avoiding the formation of foam. Transfer the reconstituted calibrator into the empty labeled snap-cap bottles supplied (CalSet Vials). Attach the supplied labels to the additional bottles. Store the aliquots immediately at -20°C. Pcrform only one calibration procedure per aliquot. All information required for correct operation is read in via the respective reagent barcode.</td><td>N/A</td></tr></table>

Substantial equivalence - comparison

The following table compares the Elecsys PreciControl Anti-CCP with the controls supplied with the predicate device.

<table><tr><td rowspan=1 colspan=3>Control Comparison</td></tr><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Elecsys PreciControl Anti-CCP</td><td rowspan=1 colspan=1>Predicate DeviceEurodiagnostica IMMUNOSCANRA Anti-CCP Test Kit (K052133)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Used for quality control of theElecsys Anti-CCP immunoassay onthe Elecsys and cobas eimmunoassay analyzers.</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>Two</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Lyophilized</td><td rowspan=1 colspan=1>Liquid</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Human serum</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Unopened:Store at 2 - 8°C until expirationdate.Reconstituted:On the analyzers at 20 - 25°C: upto 5 hoursAt -20°C: up to 1 month (freezeonly once).After thawing: use only once.</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>AnalyteConcentrationControl 1</td><td rowspan=1 colspan=1>20 U/mL Anti-CCP antibodies(human)</td><td rowspan=1 colspan=1>Negative Control(actual concentration not given)</td></tr><tr><td rowspan=1 colspan=1>AnalyteConcentrationControl 2</td><td rowspan=1 colspan=1>100 U/mL Anti-CCP antibodies(human)</td><td rowspan=1 colspan=1>Positive Control(actual concentration not given)</td></tr><tr><td rowspan=1 colspan=1>AnalyteConcentrationControl 3</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>Reference Control(actual concentration not given)</td></tr></table>

Substantial equivalence - comparison

The following table compares the Elccsys PreciControl Anti-CCP with the controls supplied with the predicate device.

<table><tr><td rowspan=1 colspan=3>Control Comparison, continued</td></tr><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Elecsys PreciControl Anti-CCP</td><td rowspan=1 colspan=1>Predicate DeviceEurodiagnostica IMMUNOSCANRA Anti-CCP Test Kit (K052133)</td></tr><tr><td rowspan=1 colspan=1>Handling</td><td rowspan=1 colspan=1>Dissolve carefully the contents ofone bottle by adding cxactly 2.0 mLof distilled water and allow to standclosed for 15 minutes to reconstitute.Mix carefully, avoiding theformation of foam.Transfer aliquots of freshlyreconstituted controls intoappropriate tubes for storage. Storethe aliquots immediately at -20°C.When mcasuring a non-barcodedcontrol, use only recommendedsample tubes, cup on tube or cup onrack. Perform only one controlprocedure per aliquot.</td><td rowspan=1 colspan=1>N/A</td></tr></table>

Roche Diagnostics   
c/o Ms. Stephanie Greeman   
Regulatory Affairs Consultant   
US Regulatory Submissions   
9115 I ague Road   
Indianapolis, IN 46250   
Re: k081338   
Trade/Device Name: Elecsys Anti-CCP Immunoassay and Elecsys PreciControl Anti-CCP Regulation Number: 21 CFR 866.5775 Regulation Name: Rheumatoid factor immunological test system Regulatory Class: Class II Product Code: NHX, JJX Dated: July 31, 2008 Received: August 4, 2008

Dear Ms. Greeman:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (MA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The

Page 2 -

FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems al 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Maria M. Chan, Ph.D.   
Acting Division Director   
Division of Immunology and Hematology Devices   
Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

# Indication for Use - Elecsys Anti-CCP Immunoassay

510(k) Number (if known): K081338

Device Name: Elecsys Anti-CCP Immunoassay

Indication For Use:

Immunoassay for the in vitro semi-quantitative determination of human IgG autoantibodies to cyclic citrullinated peptides in human serum and plasma. The results of the assay are intended to be used as an aid in the diagnosis of rheumatoid arthritis in combination with other clinical and laboratory findings.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and cobas e immunoassay analyzers.

# Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

# Indication for Use - Elecsys PreciControl Anti-CCP

510(k) Number(ifknow)K081338

Device Name: Elecsys PreciControl Anti-CCP

Indication For Use:

Elecsys PreciControl Anti-CCP is used for quality control of the Elecsys Anti-CCP immunoassay on the Elecsys and cobas e immunoassay analyzers.

# Concurrence of CDRH, Offce of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

510(k)_ K681338